Article
A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer.
Applied microbiology and biotechnology - 1 May 2020
Chung Sai-Fung, Kim Chi-Fai, Tam Suet-Ying, Choi Man-Chung, So Pui-Kin, Wong Kwok-Yin, Leung Yun-Chung, Lo Wai-Hung
Abstract excerpt
L-Arginine (L-Arg) depletion has attracted great attention in cancer therapy. Although two types of arginine-depleting enzymes, arginine deiminase (ADI) and human arginase I, are undergoing clinical trials, random site of PEGylation, low efficacy of heavy metal as co-factor, and immunogenicity limit the performance of these drugs and cause difficulty in a homogeneous production. Here we screened ten catalytic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.